BioStock: Iconovo initiates development of inhaled obesity treatment
Iconovo has filed a broad patent application for inhaled GLP-1 receptor agonists, used for the treatment of obesity and type 2 diabetes. This is a rapidly growing market, and Iconovo aims to introduce a more patient-friendly alternative to today’s injections.– This marks the first step in Iconovo’s new initiative to develop more convenient, reliable, and cost-effective treatments for obesity, the company stated.Read the full article at biostock.se : https://www.biostock.se/en/2024/05/iconovo-initiates-development-of-inhaled-obesity-treatment/ This is a